ResearchApr 29, 2022
New risdiplam data shows long-term improvement in babies with Type 1 SMA

The latest data from the FIREFISH study of risdiplam was presented at the 14th European Paediatric Neurology Society (EPNS) Congress.
The latest data from the FIREFISH study of risdiplam was presented at the 14th European Paediatric Neurology Society (EPNS) Congress.
Latest risdiplam (Evrysdi) data updates, which were presented at the 2022 MDA Clinical and Scientific Conference on 13th - 16th March.
In response to our request, Biogen has shared a community update to announce that they are moving ahead with an early-stage investigation into a new treatment for SMA that could potentially treat further unmet needs.
Applications to our 11th Call for Research Proposals (2022) are now invited.